Circulating Tumor Cell, Lung Cancer (Diagnosis)
Conditions
Keywords
Lung cancer, Circulating Tumor Cell, Cell-Free Tumor DNA, Liquid Biopsy
Brief summary
The purpose of this study is to assess clinical utility of combined circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) in the diagnosis of primary lung cancer.
Detailed description
The peripheral blood and tumor tissue samples are collected from the participants.CTC and ctDNA are analyzed from the blood samples.
Interventions
None listed
Sponsors
Samsung Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients with histology-proven lung cancer or a clinical suspicion of lung cancer * Age \>=18, \< 80 years * No previous history of cancer treatment within 5 years * Patients who agree to participate
Exclusion criteria
* Patients who have been diagnosed with malignancy within 5 years * Patients with previous history of lung cancer * Patients who have uncontrolled coagulopathy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic sensitivity of combined CTC and ctDNA | 1 year | To compared the sensitivity of combined CTC and ctDNA with those of CTC and ctDNA alone in diagnosis of primary lung cancer |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic accuracy of combined CTC and ctDNA | 1 year | To compared the accuracy of combined CTC and ctDNA with those of CTC and ctDNA alone in diagnosis of primary lung cancer |
| Diagnostic specificity of CTC and ctDNA | 1 year | To compared the specificity of combined CTC and ctDNA with those of CTC and ctDNA alone in diagnosis of primary lung cancer |
Countries
South Korea
Outcome results
None listed